Enzymotec Ltd. Granted New Patents in the United States and Australia Relevant to Phospholipid-Based Products

Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that it has been granted new patents by the U.S. Patent and Trademark Office and the Australian Patent Office for certain phospholipid-based compositions that cover several of the Company's products.

The granted patents cover a wide variety of phospholipid based compositions that include long chain poly-unsaturated fatty acids, and are pertinent to a number of Enzymotec's products, such as the K•REAL® krill oil products and additional advanced phospholipid products. These additions to Enzymotec's broad patent portfolio are the result of the Company's efforts to continually maintain and reinforce the protection of its products.

Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec, commented, "As experts in specialty phospholipid-based products, we are excited by the further strengthening of our portfolio of intellectual property with these important patents. Our products are strong leaders in the market, driven by our specialized technologies and supported with an enforceable patent portfolio. These new patents are demonstrative of our commitment to innovation and provide our customers with exceptional ingredients of the highest quality."

About Enzymotec Ltd.

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com

Forward Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the following risks: A high proportion of the sales of the InFat product is sold to end users in China and to a single company; The demand for products based on Omega-3 and in particular, premium products, such as krill oil, has declined and may continue to decline following a significant increase in manufacturing capacity by manufacturers of these products, resulting in intense competition and price pressure; Our offering of products as "medical foods" in the United States may be challenged by regulatory authorities; We rely on our Swedish joint venture partner to manufacture InFat and certain matters related to the joint venture are the subject of disagreement in arbitration proceeding; We are subject to a degree of customer concentration and our customers do not enter into long-term purchase commitments with us; We depend on third parties to obtain raw materials, in particular krill, necessary for the production of our products; We are dependent on a single facility that houses the majority of our operations; We may have to pay royalties with respect to sales of our krill oil products in the United States or Australia and any infringement of intellectual property of others could also require us to pay royalties; Potential future acquisitions of companies or technologies may distract our management, may disrupt our business and may not yield the returns expected; We anticipate that the markets in which we participate will become more competitive and we may be unable to compete effectively; We may not be able to successfully expand our production or processing capabilities; Our ability to obtain krill may be affected by conservation regulation or initiatives; Our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; and other factors discussed under the heading "Risk Factors" in the Company's Form 20-F filed with the Securities and Exchange Commission on March 2, 2015. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. 

CONTACT: KCSA Strategic Communications
         Jeffrey Goldberger / Tram Bui
         212.896.1249 / 212.896.1290
         [e-mail]